Director Cashes In on Vicarious Surgical Stock Sale

New insider activity at Vicarious Surgical ( (RBOT) ) has taken place on August 27, 2025.

Director Donald F Tang recently sold 2,753 shares of Vicarious Surgical stock, generating a total of $18,417 from the transaction.

Recent Updates on RBOT stock

In the last 24 hours, Vicarious Surgical Inc. has experienced notable developments following its Q2 earnings call. The company reported a decrease in operating expenses and net loss, maintaining a strong cash position. However, delays in clinical trials and system readiness issues have emerged as significant challenges. The appointment of Stephen From as the new CEO brings potential for future growth, yet the immediate outlook is uncertain due to concerns about development timelines. Piper Sandler lowered its price target for Vicarious Surgical, citing the company’s decision to remove its goal for first clinical use by year-end and instead focus on completing a fully integrated, production-equivalent system. This shift in priorities reflects the company’s strategic adjustments to address current hurdles and align with long-term objectives.

Spark’s Take on RBOT Stock

According to Spark, TipRanks’ AI Analyst, RBOT is a Underperform.

Vicarious Surgical’s stock score reflects significant financial challenges as a pre-revenue company with high cash burn, offset by a moderately stable balance sheet. Technical analysis indicates bearish sentiment, compounded by valuation challenges due to negative earnings. While the earnings call showed strategic advancements, supply chain delays and NYSE compliance issues pose risks. Successful clinical trials and improved cash management will be critical for future performance.

To see Spark’s full report on RBOT stock, click here.

More about Vicarious Surgical

YTD Price Performance: -52.02%

Average Trading Volume: 25,835

Technical Sentiment Signal: Strong Sell

Current Market Cap: $39.52M